FDCDDQ
PMCB icon

Federation des caisses Desjardins du Quebec’s PharmaCyte Biotech PMCB Stock Holding History

Federation des caisses Desjardins du Quebec’s Portfolio PMCB Stock Details PMCB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-7
Closed -$17 – 2530
2022
Q3 		$17 Hold
7
– – ﹤0.01% 2495
2022
Q2 		$16 Hold
7
– – ﹤0.01% 2529
2022
Q1 		$16 Hold
7
– – ﹤0.01% 2540
2021
Q4 		$18 Hold
7
– – ﹤0.01% 2516
2021
Q3 		$22 Buy
+7
New +$25 ﹤0.01% 2544

Other funds holding PMCB

AC
Ayrton Capital Westport, Connecticut $14.7M AUM 12.82% 1-Year Est. Return
KPF
K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EPM
Equitec Proprietary Markets Chicago, Illinois $559M AUM 230.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
IEFM
IQ EQ Fund Management Dublin 2, Ireland $1.32B AUM 31.52% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Federation des caisses Desjardins du Quebec's PMCB Position: Q4 2022 in Review

Federation des caisses Desjardins du Quebec sold out of PharmaCyte Biotech (PMCB) in Q4 2022, closing a stake of 7 shares — an estimated $17 sold.

Federation des caisses Desjardins du Quebec first reported a position in PMCB in Q3 2021 and held it in 5 quarters. The position peaked at $22 in Q3 2021. 30 funds tracked by Wall St. Rank hold PMCB as of Q4 2022.

  • Federation des caisses Desjardins du Quebec reported no remaining PharmaCyte Biotech position as of Q4 2022 after selling out during the quarter.
  • Federation des caisses Desjardins du Quebec sold 7 PharmaCyte Biotech shares in Q4 2022, an estimated $17.
  • Federation des caisses Desjardins du Quebec first reported a position in PharmaCyte Biotech in Q3 2021 and held it in 5 quarters.
  • Federation des caisses Desjardins du Quebec's PharmaCyte Biotech position peaked at $22 in Q3 2021.
  • 30 funds tracked by Wall St. Rank held PharmaCyte Biotech as of Q4 2022.

Based on Federation des caisses Desjardins du Quebec's 13F filing for Q4 2022, filed 15 Aug 2024.